You are here

P&T® Journal contents for June 2007


FDA Update
The new PDUFA bill might not be strong enough to overcome the weaknesses of the current system of post-marketing surveillance of new drugs.
Stephen Barlas
Health Care & Law
At one time, the “War on Drugs” centered on illicit, addictive agents. This article addresses the growing misuse of “legitimate” prescription drugs.
Robert I. Field, JD, MPH, PhD
Meeting Highlights
The author discusses the biology and etiology of lymphoma, genetic factors, standard chemotherapy, novel antibody therapy, clinical trials, and adverse drug effects.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
Studies presented at the meeting focused on agents for acute coronary syndrome and carotid artery intima media thickness; optimal medical therapy with or without percutaneous coronary intervention; and a thrombin receptor agonist designed to reduce clinical events without increasing bleeding.
Reuben B. David
Continuing Education Credit
The author reviews the etiology and stages of non-inflammatory and inflammatory manifestations of acne along with various therapies, including topical and oral antibiotics and retinoids; hormones; and nutritional supplements.
Noah S. Scheinfeld, JD, MD


David Nash, MD, MBA, describes this year’s National Healthcare Quality Report and points out some of the areas still needing improvement, such as acute care, prenatal care, and ambulatory care.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, suggests ways of avoiding mixups with look-alike drugs (e.g., better labeling and storage) and for preventing errors when the hospital staff uses a double-checking procedure.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses a congressional bill that, if passed, would allow changes to the Medicare Part D drug benefit and might simplify formulary decision-making.
Stephen Barlas
P&T presents the latest studies and information about FDA approvals, drug indications, and industry updates.
Drug Forecast
The authors review oxymorphone HCl (Opana) for moderate-to-severe pain.
Jennifer Lind, PharmD Candidate, Jaclyn Lennard, PharmD Candidate, Patty Ghazvini, PharmD, Marlon Honeywell, PharmD, and Phillip Treadwell, PharmD